Navigation Links
FDA Approves First-of-its-Kind Drug to Treat Rare Blood Disorder

The U.S. Food and Drug Administration (FDA) today approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria// (PNH), a rare type of blood disorder that can lead to disability and premature death. Soliris is classified as an Orphan Drug and is a new molecular entity containing an ingredient not previously marketed in the United States.

"This product is important in that it offers a treatment other than blood transfusion that may help this small population of patients who are often very ill," said Steven Galson, M.D., M.P.H., director, Center for Drug Evaluation and Research, FDA. "This approval is one of multiple examples of how the orphan products program can benefit the public health with urgently needed products that would otherwise not be commercially available."

PNH, which usually develops in adults, is a disease characterized by red blood cells that develop abnormally. Once the abnormal cells are present in the bloodstream, naturally occurring proteins (called the complement system) designed to destroy bacteria and other infection-causing organisms break these cells down. This leads to abnormally darkened urine and, more importantly, causes anemia. Depending upon the severity of the disorder, patients with PNH may have pain, fatigue and debilitating weakness, the need for frequent blood transfusions, blood clots, and life-threatening or fatal strokes, heart attacks and intestinal disease.

Soliris does not cure PNH, but treats the breakdown of red blood cells, the most common characteristic of PNH. Soliris acts to block the complement system activity, including the destruction of PNH red blood cells.

FDA based its approval on the company's randomized, double-blind, placebo-controlled clinical study of 87 patients with PNH and a series of other clinical studies. The controlled study showed that over a 26-week period half of the participants receiving Soliris had stab
'"/>




Page: 1 2

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2
...i, Feb 13 Valentine Day is assuming a new importa...ion in booming with Almost half// its population b...India has shed off old inhibitions and embraced li... Western festival of Valentine's Day despite oppos...
...een found through an animal study that Aspartame c... that drinking four to five 20-ounce bottles of di... the //cause of cancers. The study would be publi...onmental Health Perspectives, an US government-run...
...tempting to learn a new task, taking short breaks ...sy, according to a new study conducted by Massachu...Foster and Matthew Wilson, working at the Massachu...idge, found that rats' brains 'replay' their exper...
...ia in the year 2005 planned to begin stem cell res...ers passing the Proposition 71. But the legal chal...als now say that it would take spring 2007 before ..., president of the California Institute for Regene...
Other Medicine News:Health News:Valentine Day Becoming Popular In India 2Health News:Task Learning Made Simple By Taking Short Breaks 2Health News:Momentum of Stem cell research impeded by legal challenges 2
(Date:7/22/2008)...Including Lantus(R) and Apidra(R) Resulted in Sign... Diabetes, Whatever the Algorithm ... /- Results from the "Adjust to,Targe...ithm to Carbohydrate,Counting for Adjustment of Me... the American Diabetes Association,s (ADA) medical...
(Date:7/22/2008)...nd Validated by Columbia University Medical Center...MicroRNA Technology, The Test Differentiates Squ...r (NSCLC), Classifying Squamous-Cell Carcinoma of ... Specificity of 90 Percent,This is the First CLIA ...ty as Biomarkers for Accurate Diagnosis o...
(Date:7/22/2008)...Suggests That Ekkyo,s New Approach of LASH (Laser ... Scar Healing Physiology, MARSEILLES, France, Jul...wave Technology) a photomedicine company, which de... scar prevention and reduction, announced today,th... Surgery and Medicine*,reporting the results of a ...
(Date:7/21/2008)... 21 /- The SEAS (Simvastatin and Ezet...he effects of intensive,cholesterol lowering with ...zetimibe (10 mg daily) in patients with aortic ste...lockage of the aortic valve in,the heart) is a rel...rn,populations. Left untreated, it can progress to...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4Cardiogenesis Reports First Quarter 2008 Results 19431 1Cardiogenesis Reports First Quarter 2008 Results 19431 2Cardiogenesis Reports First Quarter 2008 Results 19431 3Cardiogenesis Reports First Quarter 2008 Results 19431 4Cardiogenesis Reports First Quarter 2008 Results 19431 5Cardiogenesis Reports First Quarter 2008 Results 19431 6Discover Talent Management Best Practices June 4 6 Registration Ends Friday 19429 1Discover Talent Management Best Practices June 4 6 Registration Ends Friday 19429 2Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 1Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 2Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 3AEterna Zentaris to Present at Upcoming Rodman 26 Renshaw Global Healthcare Conference and AUA Annual Meeting 5424 1AEterna Zentaris to Present at Upcoming Rodman 26 Renshaw Global Healthcare Conference and AUA Annual Meeting 5424 2
...RE)--Apr 16, 2007 - Antigenics Inc.,(NASDAQ: AGEN)...ata,from a Phase 1/2 investigator-sponsored trial ...cophage(R) (vitespen) in,recurrent, high-grade gli...ociation of Neurological Surgeons (AANS; abstract,...onducted at the,Brain Tumor Research Center at the...
...ctive Anti-VEGF Antibodies Inhibited Tumor Growth ...er Model -, , - Peregrine,s Antibodies that Select...Have Advantages over Non-Selective Approaches - , ...ly Human,Antibody Support , Advancing Peregrine,s ...ANGELES and TUSTIN, Calif., April 16, 2007,/PRNews...
Other Medicine Technology:Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 2Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 3Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5
...the most comprehensive family of lightweight stand...incision, Glaucoma filtration, and Vitreoretinal u... with minimal tissue trauma and minimal peripheral...ilable in 18, 20, and 20-23Ga tapered designs. Add...
...the most comprehensive family of lightweight stand...incision, Glaucoma filtration, and Vitreoretinal u... with minimal tissue trauma and minimal peripheral...ilable in 18, 20, and 20-23Ga tapered designs. Add...
Centuries of German Craftsmanship have produced the finest surgical instrumentation in the world. Ocutek now makes them available to you! Only holders of the coveted Meisterbrief certificate, which r
Centuries of German Craftsmanship have produced the finest surgical instrumentation in the world. Ocutek now makes them available to you! Only holders of the coveted Meisterbrief certificate, which r
Medicine Products: